Deep Brain Stimulation Market worth $1.15 Billion by 2030 - Exclusive Report by The Insight Partners
16 août 2023 08h37 HE
|
The Insight Partners
Pune, India, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Deep brain stimulator (DBS) is a device comprising a brain-oriented pacemaker (an implantable pulse generator) that sends electrical stimulation via...
Alzheimer’s Disease Biomarkers Market Predicted to Reach USD 1.7 billion by 2031, Expanding at a 7.5% CAGR Says, Transparency Market Research Inc.
14 août 2023 07h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global Alzheimer’s disease biomarkers market is expected to be valued at US$ 953.54...
Alzheimer's Disease Market Predicted to Surge at a CAGR of 20% During the Study Period (2019–2032), Assesses DelveInsight
02 août 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alzheimer's Disease Market Predicted to Surge at a CAGR of 20% During the Study Period (2019–2032), Assesses DelveInsight The Alzheimer's disease...
The Joint Commission, in Collaboration with the Alzheimer’s Association, Launches Memory Care Certification for Assisted Living Communities
11 juil. 2023 12h30 HE
|
The Joint Commission
OAKBROOK TERRACE, Ill., July 11, 2023 (GLOBE NEWSWIRE) -- The Joint Commission, in collaboration with the Alzheimer’s Association, launched Memory Care Certification for Assisted Living Communities...
Neuronascent to Present New Parkinson’s Model Data at AAIC 2023 for the Alzheimer’s Disease Investigational Therapy, NNI-362
28 juin 2023 06h00 HE
|
Neuronascent, Inc.
ROCKVILLE, Md., June 28, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., today announced its abstract titled, Clinical Stage Alzheimer’s therapy, NNI-362 Promotes TH+ Neurons Associated with a Reversal...
Landmark Study Investigating Novel Alzheimer’s Biomarkers Advances to Data Analysis Stage
14 juin 2023 06h00 HE
|
Global Alzheimer's Platform Foundation
WASHINGTON, DC, June 14, 2023 (GLOBE NEWSWIRE) -- Up to 50 percent of people in the U.S. with Alzheimer’s receive an imprecise or inaccurate diagnosis of their cognitive condition. The tools...
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET
01 juin 2023 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., June 01, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells
12 avr. 2023 08h00 HE
|
Vaccinex, Inc.
GPCRs play a key role in many important physiological processes which makes them an important class of drug targets; however, their biophysical properties have made many GPCRs “difficult to drug” New...
Neuronascent Announces the Expansion of its Board of Directors
12 avr. 2023 06h00 HE
|
Neuronascent, Inc.
ROCKVILLE, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a clinical-stage, neuron generating, biopharmaceutical company, is pleased to announce the addition of industry leader Emer...
ZyVersa Therapeutics Announces Article Published in Brain Pathology Addressing Inflammasome Signaling Proteins in Alzheimer’s Disease
10 avr. 2023 09h07 HE
|
ZyVersa Therapeutics
Increased inflammasome protein expression, NLRP1, NLRP3, ASC, and caspase-1, occurs early in Alzheimer’s disease (AD), indicating a role for multiple types of inflammasomes in disease development...